Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANAVEX2-73 in Adult Patients with Rett Syndrome
2019-004345-32Phase 2Unknown
- Sponsor
- Anavex Life Sciences Corp.
- Start
- Feb 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Rett syndrome (RTT) comparing blarcamesine with placebo (2 arms). Primary endpoint: Safety and tolerability of blarcamesine (ANAVEX2-73). Status: unknown.
02
Drugs
blarcamesine
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on 2019-004345-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004345-32.